Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q2 revenue increased 50% year over year to $185.6 million, the loss was narrower than expected, and 2026 sales guidance was raised; shares gained 23.8% and were testing $189.50 resistance on August 20.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Improving Margins ⢠Ongoing Losses GKOS has strong liquidity and improving quarterly cash flow/margins, but persistent losses and high sales/book multiples make the stock's valuation demanding.
Price Behavior
Key Price Behavior Insights: ⢠Sharp breakdown ⢠Support test ⢠Weak momentum Support Level: $166.70â$171.00 Resistance Level: $179.50â$185.70 GKOS fell 11.7% over the last month and broke down sharply to $167.25; near-oversold conditions may support a bounce if $166.70â$171.00 holds, but the trend remains negative below $179.50.
Sentiment & News
Key News Insights: ⢠Raised 2026 Guidance ⢠Product Growth ⢠Mixed Institutional Flows Glaukos' strong iDose TR and Epioxa-driven growth, higher guidance, and expanding margins support a bullish outlook despite mixed institutional trading.
AI Summary
Glaukos's strong iDose and Epioxa launches and 82% gross margin shift the thesis from pipeline growth to proving durable operating leverage and cash generation; at ~15.6x sales, investors should wait for sustained reimbursement-supported adoption and profitability before underwriting further upside.
Description
Glaukos Corporation develops ophthalmic medical devices and pharmaceutical therapies for glaucoma, corneal conditions, and retinal diseases. Its commercial portfolio centers on micro-bypass stents placed with cataract surgery to improve aqueous outflow in patients with mild-to-moderate open-angle glaucoma, while its pipeline includes a multi-stent system for refractory cases and a micro-scale injectable implant for sustained drug delivery. The company sells through a combination of direct sales and distributors in the U.S. and internationally and is headquartered in San Clemente, California, having been incorporated in 1998.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 20 | Aug 27 | GKOS | Glaukos Corporation | Q2 revenue increased 50% year over year to $185.6 million, the loss was narrower than expected, and 2026 sales guidance was raised; shares gained 23.8% and were testing $189.50 resistance on August 20. | Closed | -1.6% |